A one-day event on Thursday, March 29th 2012.
To be held at the Royal Pharmaceutical Society, 1 Lambeth High Street, London, SE1 7JN
Why this meeting?
The UK government is striving to curb levels of national debt, and healthcare systems are even more vulnerable than usual to spending cuts.
This meeting therefore hopes to consider a whole series of questions on the subject of value in healthcare, including: :
l
If we have to choose what to spend money on in healthcare systems, can we identify where we find value in those systems?
l
Should parts of the healthcare system be cut back?or even axed?
l
Alternatively, should investments in healthcare be applied? If so, where?
l
How can healthcare be made more efficient, without comprising the health of patients?
l
And how can preventive medicine be encouraged, so that populations become healthier, and less likely to need expensive services from healthcare systems? Surprisingly, little or no hard data exists across Europe’s fragmented and opaque healthcare systems to help policymakers gain answers to these questions?which are all centered around the subject of the values we hold in healthcare.The only widely-recognised tool in the measurement of value in health is health technology assessment (HTA , as practiced by the National Institute for Health and Clinical Excellence (NICE .But the methods and processes of both HTA and NICE have been challenged by various categories of healthcare stakeholders.Policymakers at NICE hold contrasting views, for example, to doctors, patients and industry on what value society expects from healthcare systems.The stark truth is that no consensus exists about what we?the disparate healthcare stakeholders?want from healthcare systems.
Hence, this unique conference
On Thursday, March 29th 2012, Engage Health will be bringing influential healthcare stakeholders together at the Royal Pharmaceutical Society, London. The aim is to gain an understanding of what society sees as value for modern-day national healthcare systems.As part of the dialogue, Engage Health has invited speakers from outside the UK to provide insights about how their countries’ healthcare systems attempt to draw the greatest value out of the money spent on nationalised healthcare.The meeting will look at HTA as a case study, and contemplate the problems of developing tools that hope to measure value within healthcare
.
What will happen at the meeting?
The meeting’s programme includes presentations from patient groups, senior policymakers, commissioners, industry and providers. The meeting’s conclusions will be published as a WHITE PAPER, to stimulate further debate and action.[The White Paper written after the Engage Health Alliance meeting in Brussels in November 2011, entitled ‘A Crisis in Healthcare?Closing the Stakeholder Gap’, will be publicly available on the Engage Health Alliance website from late February 2012 onwards, so that you can get an idea of what an Engage Health Alliance White Paper looks like, and hopes to achieve.]
Who is speaking?
Confirmed speakers currently include:
l
Josie Godfrey, Head of Policy and Co-ordination, National Specialised Commissioning Team, NHS.
l
Brian Griiffin, CEO Medco International.
l
Aidan Halligan, Director of Education, University College London Hospital [provisional].
l
Henry Purcell, Senior Fellow in Cardiology; Director, Cardiovascular Pathology of Obesity Research Group, Royal Brompton Hospital, London; and Editor-in-Chief, British Journal of Cardiology.
l
Katja Rupp, Manager, Deutsche Gesellschaft für Versicherte und Patienten e.V. (DGVP [German Society for Insured Patients].
l
Karen Taylor, Director, Centre for Health Solutions, Deloitte UK.
l
Mark Wilkinson, Director, Life Sciences Innovation, NHS.
l
Andrew Wilson-Webb, Chief Executive, Rarer Cancers Foundation (RCF .
l
Alexandra Wyke, CEO, PatientView, will talk about the results of a study among 500 patient groups on the meaning of value in healthcare.
How you can be involved in the discussion
With the help of a number of facilitators, participants at the meeting will be split into a number of cross-stakeholder groups. Each of the groups will be challenged with the task of maintaining the UK NHS budget at its current level over the next five years?while improving both the life expectancy of people with chronic illness, and their quality of life. In designing any health-reform packages.
At the end of the final session of the meeting, each cross-stakeholder group will report its findings to the conference.
TO READ THE FULL AGENDA, please
click here
TO REGISTER for attendance, please
click here.
Engage Health Alliance Europe,
Add: 12 High Street, Stevenage, Hertfordshire, SG1 3EJ, UK
Tel: +44-(0 1438-870-066
Email:
events@engagehealth.eu
Web:
http://www.engagehealth.eu
PatientView, is a co-founder of the Engage Health Alliance Europe
In a study to be published this week in the early edition of the Proceedings of the National Academy of Sciences, the researchers say they have paved the way toward an effective vaccine by identifying eight antigens -- molecules in the invading bacteria that trigger an immune response -- common in mice and human infections.
"These antigens will provide the research community with a foundation for developing a protective salmonella vaccine," said Stephen McSorley, an immunologist and associate professor in the UC Davis Center for Comparative Medicine, in a news release.
Every year, about 40,000 cases of salmonellosis are confirmed in the U.S., according to the Centers for Disease Control and Prevention, but because most cases not diagnosed and therefore not reported, the actual number of infections may be 1.2 million or more.
Children, younger than five, are the most likely to get salmonellosis. About 400 people perish each year because of acute infections.
In working toward a vaccine, the UC Davis-led research team said it created an array, or collection, of 2,700 proteins -- about 60 percent of all proteins produced by Salmonella bacteria. The researchers found that 117 of those proteins behaved as antigens when mixed with blood serum from Salmonella-infected mice, triggering an immune response to defend against the bacteria. Fourteen of those proteins were common to all four strains of mice involved in the study.
The researchers also identified 14 proteins that served as antigens in the blood serum from Malawian children infected with Salmonella. Eight of those 14 proteins, or 57 percent, were among the 117 antigens identified in the mice.
McSorley said discovery of the eight antigens in both mouse and human infections suggests that some of these antigens might be used in developing a vaccine to protect against Salmonella, and that the mouse model of Salmonella would be useful before the research moves into clinical trials.
Collaborating on the project, which was funded by The National Institutes of Health; the Wellcome Trust and the pharmaceutical company GlaxoSmithKline, were UC Irvine; the University of Malawi, Chichiri, Malawi; Novartis Vaccines Institute for Global Health, Sienna, Italy; and the University of Birmingham, England.
No comments:
Post a Comment